Federal Court Upholds Reinstatement of NJ Worker Fired for Cannabis Test

Third Circuit Defers to State Cannabis Employment Statute

The Third Circuit ruled that federal courts lack jurisdiction to override New Jersey's cannabis employment protections, deferring to the state Civil Service Commission's reinstatement order. The unanimous three-judge panel held that the employer—a logistics company operating a warehouse in Middlesex County—failed to demonstrate that the worker's off-duty cannabis use posed a workplace safety risk or violated federal law preempting state protections.

The decision stems from a 2023 termination. The worker had been employed since 2019 in a non-safety-sensitive role. He tested positive during a random drug screen. The employer cited a zero-tolerance policy predating New Jersey's 2021 legalization statute.

New Jersey's Cannabis Employment Framework

New Jersey's Cannabis Regulatory Act bars adverse employment actions based solely on off-duty cannabis use, with narrow exceptions for safety-sensitive positions and federal contract compliance. The statute, codified at N.J.S.A. 24:6I-52, took effect February 22, 2021, alongside adult-use sales launch.

Key provisions include:

• Employers can't refuse to hire or terminate employees for off-duty cannabis consumption unless the role is safety-sensitive or subject to federal drug-testing mandates.
• Positive drug tests alone don't establish workplace impairment.
• Employers must demonstrate actual impairment during work hours to justify disciplinary action.

The employer argued the warehouse role involved forklift operation, qualifying as safety-sensitive. The state administrative law judge rejected that claim. The worker's duties were primarily clerical. Forklift use was incidental.

Administrative Record and Timeline

The worker filed a complaint with the New Jersey Division on Civil Rights in April 2023, leading to a 14-month administrative process that culminated in a reinstatement order with full back pay. The administrative law judge issued an initial decision in October 2023, adopted by the Civil Service Commission in February 2024. The employer appealed to federal district court in March 2024, which dismissed for lack of subject-matter jurisdiction. The Third Circuit affirmed that dismissal September 22, 2026.

The employer's federal appeal rested on two arguments: that the Controlled Substances Act preempts state cannabis employment protections, and that the worker's role met the federal safety-sensitive exception. The Third Circuit found neither persuasive, noting that the CSA doesn't compel private employers to terminate workers for lawful state conduct and that the administrative record supported the state's factual findings on job duties.

Implications for Multi-State Employers

The ruling creates binding precedent across Pennsylvania, New Jersey, Delaware, and the U.S. Virgin Islands—the Third Circuit's jurisdiction—and signals that federal courts will defer to state cannabis employment frameworks absent clear federal preemption. Employers in those states must now work through a patchwork of protections: New Jersey and Pennsylvania prohibit discrimination for off-duty use, while Delaware's statute is narrower and the Virgin Islands has no comparable law.

Multi-state employers with operations in Third Circuit states face heightened compliance risk if drug-testing policies don't distinguish between safety-sensitive and general roles or fail to assess actual impairment.

The decision doesn't affect employers subject to federal drug-testing mandates under Department of Transportation regulations or federal contracts requiring drug-free workplace certifications. Those exceptions remain intact under New Jersey law.

Employer Drug-Testing Policy Adjustments

Cannabis employment attorneys report a 40% increase in policy-revision requests from New Jersey employers since the Third Circuit docket entry appeared in August, according to the New Jersey chapter of the National Employment Law Project. Recommended adjustments include:

• Reclassifying roles to clearly delineate safety-sensitive positions under state and federal definitions.
• Replacing blanket zero-tolerance policies with impairment-based protocols using observable behavior checklists.
• Updating employee handbooks to reflect state-specific protections and federal exceptions.

Employers that fail to update policies risk state civil-rights complaints, back-pay liability, and potential punitive damages under New Jersey's Law Against Discrimination, which the Cannabis Regulatory Act incorporates by reference.

Related Litigation in Other Jurisdictions

At least six other federal circuits have pending appeals involving state cannabis employment protections, with outcomes likely to hinge on whether state statutes include explicit safety-sensitive carve-outs. The Ninth Circuit is reviewing a similar California case involving a warehouse worker terminated after a positive test; oral arguments are scheduled for November 2026. A pending appeal from a Maine employer challenging that state's 2018 employment protections sits before the First Circuit.

The Third Circuit's decision doesn't address the question of whether employers can discipline workers for on-duty impairment detected through non-THC biomarkers, a question pending in a separate New Jersey case involving roadside sobriety testing. That case, currently before the New Jersey Supreme Court, may determine whether employers can rely on emerging impairment-detection technologies beyond traditional urinalysis.

For full background on cannabis employment protections across U.S. states, see the CannIntel topic hub on cannabis employment protections.